is associated with growth and development of B-cells.
4) confirmed that DEFA6, B-cell CLL/lymphoma 11A (BCL11A), interleukin 33 (IL33), BMP7, ATP binding cassette subfamily B member 1 (ABCB1), CCND2, TNFRSF1B, fibronectin 1 (FN1), semaphorin 6A (SEMA6A), and galanin (GAL) were upregulated and that PDGFC, prostaglandin-endoperoxide synthase 2 (PTGS2), Wnt family member 11 (WNT11), transforming growth factor beta 2 (TGFB2), dickkopf WNT signaling pathway inhibitor 1 (DKK1), bone marrow stromal cell antigen 2 (BST2
), GATA binding protein 2 (GATA2), gap junction protein beta 6 (GJB6), SMARCA1, and ADAM metallopeptidase with thrombospondin type 1 motif 6 (ADAMTS6) were downregulated in CTC-MCC-41 cells compared with HT-29 cells.
report their investigation of bone marrow stromal antigen 2 (BST2
; also known as CD317, tetherin, and HM1.24) as a plasma biomarker in 152 patients with CRC.
The expression of bone marrow stromal protein 2 (BST2
), which can be associated with the development of bone metastasis in human breast cancer, is significantly increased in bone metastatic breast cancer cell lines and tumor tissue compared with nonbone metastatic breast cancer cell lines.
Abbreviations, CD numeration, and alternate names: DEC-205 (CD205), B220 (CD45R), PDCA-1 (plasmacytoid DC Ag-1; CD317; Bst2
), Siglec H (Sialic acid-binding immunoglobulin-like lectin H), Langerin (CD207), CD141 (BDCA-3), CD1c (BDCA-1), and CD303 (BDCA-2).
(143-146) One study has suggested Serpine10 and BIN1 as potential markers and BST2
and LCK as potential therapeutic molecular targets.
This set of IFN-stimulated genes (ISGs) contained several genes with previously known direct antiviral activity, such as APOL9, BST2
(Tetherin), DDX58 (RIG-1), EIF2AK2 (PKR), IFITM3, ISG15, MX2, OAS-1, PARP12, or TRIM.